Signals
6Neurotrophic keratitis acquires recombinant nerve growth factor therapy
Cenegermin (recombinant nerve growth factor) maturity, follow-on programs, and structured corneal-care pathways are reshaping neurotrophic keratitis management.
Retinal vein occlusion therapy options widen past first-generation anti-VEGF
Faricimab and high-dose aflibercept extension, structured macular edema management, and emerging mechanism programs are reshaping retinal vein occlusion management.
Proliferative diabetic retinopathy therapy reshapes around anti-VEGF
Anti-VEGF first-line for proliferative diabetic retinopathy, panretinal photocoagulation as alternative or combination, and emerging mechanism programs are reshaping PDR management.
Allergic conjunctivitis therapy widens past topical antihistamines
Topical multi-action options, novel mechanism programs, and emerging biologic-pathway therapy are reshaping allergic conjunctivitis management.
Presbyopia pharmacological options widen past pilocarpine
Pilocarpine maturity, follow-on miotic-class programs, and emerging non-miotic mechanism programs are reshaping presbyopia management.
Thyroid eye disease therapy grows past teprotumumab
Teprotumumab maturity plus follow-on IGF-1R-targeted programs and novel non-IGF-1R mechanism classes are restructuring thyroid eye disease management.
Snapshots
4Retinal vein occlusion therapy reference (2026)
Reference snapshot of RVO therapy across acute and ongoing macular edema management plus systemic care integration.
Allergic conjunctivitis therapy reference (2026)
Reference snapshot of allergic conjunctivitis therapy across mild seasonal, persistent, severe, and emerging tiers.
Presbyopia therapy reference (2026)
Reference snapshot of presbyopia management across optical, surgical, and pharmacological approaches.
Thyroid eye disease therapy reference (2026)
Reference snapshot of thyroid eye disease therapy across active and stable phases.
Explained
4What is retinal vein occlusion?
Plain-language primer on retinal vein occlusion, why it is a vascular event, and what modern therapy can offer.
What is allergic conjunctivitis?
Plain-language primer on allergic conjunctivitis, the different types, and what the modern range of therapy can offer.
What is presbyopia?
Plain-language primer on presbyopia, why it affects nearly everyone with age, and what the modern range of options can offer.
What is thyroid eye disease?
Plain-language primer on thyroid eye disease, why it is linked to thyroid problems, and what modern therapy can offer.